Business Description
INmune Bio Inc
NAICS : 325412
SIC : 2834
Description
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.73 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -0.52 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.69 | |||||
| Beneish M-Score | 9.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -17.7 | |||||
| 3-Year EPS without NRI Growth Rate | -19.2 | |||||
| 3-Year FCF Growth Rate | -144.7 | |||||
| 3-Year Book Growth Rate | 45 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.82 | |||||
| 9-Day RSI | 61.86 | |||||
| 14-Day RSI | 59.76 | |||||
| 6-1 Month Momentum % | -26.57 | |||||
| 12-1 Month Momentum % | -18.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.67 | |||||
| Quick Ratio | 9.67 | |||||
| Cash Ratio | 8.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -6667.95 | |||||
| Net Margin % | -7076.59 | |||||
| ROE % | -41.21 | |||||
| ROA % | -32.87 | |||||
| ROIC % | -129.61 | |||||
| ROC (Joel Greenblatt) % | -2149.69 | |||||
| ROCE % | -32.45 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 347.92 | |||||
| PB Ratio | 2.35 | |||||
| Price-to-Tangible-Book | 3.17 | |||||
| EV-to-EBIT | -3.68 | |||||
| EV-to-EBITDA | -3.68 | |||||
| EV-to-Revenue | 245.05 | |||||
| EV-to-Forward-Revenue | 6183.76 | |||||
| EV-to-FCF | -4.03 | |||||
| Price-to-Net-Current-Asset-Value | 3.22 | |||||
| Price-to-Net-Cash | 4.01 | |||||
| Earnings Yield (Greenblatt) % | -27.17 |
